She wants to split the MAHA and MAGA coalition in two
Within the Trump administration, a quiet contest over the soul of American health policy has surfaced through the brief firing and swift reinstatement of FDA vaccine regulator Vinay Prasad — a sequence of events that lasted two weeks but revealed fractures years in the making. On one side stands Robert F. Kennedy Jr.'s reform coalition, which sees itself as a genuine challenge to pharmaceutical industry power; on the other, MAGA influencer Laura Loomer, whose opposition to Prasad traced not to ideology but to her alignment with a drug manufacturer whose product Prasad had flagged as unsafe. That White House chief of staff Susie Wiles ultimately brokered Prasad's return suggests the architecture of power in this administration remains contested, with each personnel decision becoming a proxy war for something far larger.
- Trump fired FDA regulator Vinay Prasad on the word of an influencer who found a years-old Bernie Sanders post — and the decision unraveled almost immediately.
- RFK Jr. and FDA Commissioner Marty Makary mounted an urgent, relentless campaign through chief of staff Susie Wiles to reverse the firing before it could permanently damage their health reform agenda.
- The reinstatement exposed what the firing obscured: Loomer was not policing loyalty but protecting Sarepta Therapeutics, a pharmaceutical company whose drug Prasad had moved to pull from shelves.
- A senior official warned that Loomer is actively working to 'split the MAHA and MAGA coalition,' and has already set her sights on other members of Kennedy's inner circle.
- The White House issued a statement celebrating health policy wins while remaining conspicuously silent on the internal war — leaving the question of who actually controls health policy visibly unresolved.
A two-week sequence of firing and rehiring at the FDA has cracked open one of the Trump administration's most consequential internal conflicts. Vinay Prasad, a vaccine regulator, was pushed out after MAGA influencer Laura Loomer surfaced old social media posts suggesting he had once supported Bernie Sanders. To Loomer, that history was disqualifying. To the administration's health reform wing, it was irrelevant.
Robert F. Kennedy Jr. and FDA Commissioner Marty Makary moved quickly to fight back. Working through chief of staff Susie Wiles, they made a direct case to Trump: Prasad was not anti-Trump, and losing him would damage the broader MAHA — Make America Health Again — coalition they had spent months assembling. The argument landed. Trump rehired Prasad last week.
But the reversal clarified rather than resolved the conflict. Loomer's campaign against Prasad was not purely ideological. She had aligned herself with Sarepta Therapeutics, a pharmaceutical company whose muscular dystrophy drug Prasad had flagged as unsafe and moved to pull from the market. Her push to remove him, in other words, served corporate interests as much as loyalty tests.
That distinction is now shaping how Kennedy's allies read the broader threat. One senior official described Loomer's effort as an attempt to split the MAHA and MAGA coalitions apart — and she has already turned her attention to other members of Kennedy's team, including his principal deputy chief of staff and Trump's surgeon general nominee. The White House, for its part, issued a statement highlighting the health team's accomplishments while saying nothing about the conflict itself. The silence may be the most telling detail of all.
Inside the Trump White House, a quiet power struggle over health policy has erupted into the open, revealing deep fractures in what was supposed to be a unified movement. At the center of the conflict is Vinay Prasad, a vaccine regulator at the Food and Drug Administration, whose firing and subsequent rehiring in the span of two weeks has exposed a fundamental clash between two competing visions of how the administration should operate.
Two weeks ago, Trump forced Prasad out of his position at the FDA. The decision came at the insistence of Laura Loomer, a MAGA influencer who had dug into Prasad's old social media posts from the pandemic and found evidence that he had once identified as a Bernie Sanders supporter. To Loomer, this was disqualifying—proof that Prasad lacked sufficient loyalty to Trump. But the move immediately triggered resistance from within the administration's own health apparatus. Robert F. Kennedy Jr., the Health and Human Services Secretary, and Marty Makary, the FDA commissioner, both objected strenuously. They saw Prasad as essential to their broader health reform agenda, which they had branded as "Make America Health Again"—a deliberate echo of Trump's own MAGA slogan.
What happened next revealed the real architecture of power in this White House. Rather than accept the firing, Kennedy and Makary worked through Susie Wiles, the president's chief of staff, to make their case directly to Trump. According to a senior administration official, they emphasized a simple point: Prasad was not anti-Trump. The official described the effort in terms that suggested both frustration and determination. "After Vinay left, Marty and Bobby worked very, very, very hard through Susie Wiles to tell the president that Vinay was not anti-Trump," the official said. "The MAHA movement is an expansion of the MAGA, sort of, you know, big tent."
The intervention worked. Last week, Trump rehired Prasad. But the reversal did not resolve the underlying tension—it exposed it. The real issue, according to officials, is not Prasad himself but rather a fundamental disagreement about the direction of health policy and who gets to shape it. Loomer's opposition to Prasad was not random. She had allied herself with Sarepta Therapeutics, a pharmaceutical manufacturer whose drug for Duchenne muscular dystrophy, called Elevidys, had been flagged as unsafe by Prasad the previous month. Prasad had pushed the FDA to ask the company to stop selling the drug. In other words, Loomer was not simply enforcing ideological purity—she was protecting corporate interests.
This distinction matters because it signals something larger: a rift between Kennedy's health reform coalition and what one senior White House official described as Loomer's effort to "split the MAHA and MAGA coalition" in two. Kennedy and his allies see themselves as part of a genuine movement to reform American health, one that includes both MAGA loyalists and health professionals willing to challenge pharmaceutical industry influence. Loomer, by contrast, appears to be building a different coalition—one aligned with corporate pharmaceutical interests and focused on enforcing personal loyalty to Trump above all else.
The conflict is not over. Loomer has already trained her attention on other members of Kennedy's team, including Stefanie Spear, Kennedy's principal deputy chief of staff, and Casey Means, Trump's nominee to be surgeon general. When asked about the reporting, Loomer declined to comment. The White House, through spokesperson Kush Desai, issued a statement emphasizing the achievements of Kennedy's health team: restaurant chains dropping artificial ingredients, FDA reforms to accelerate drug approvals, and a broader mandate to make America healthy again. The statement was notably silent on the internal conflict, on Loomer, or on the question of who actually controls health policy in this administration. What remains clear is that the answer to that question is still being fought out, one firing and rehiring at a time.
Citações Notáveis
After Vinay left, Marty and Bobby worked very, very, very hard through Susie Wiles to tell the president that Vinay was not anti-Trump.— Senior administration official
I think she wants to split the MAHA and MAGA coalition. She wants to split them in two.— Senior White House official, on Laura Loomer's strategy
A Conversa do Hearth Outra perspectiva sobre a história
So Susie Wiles stepped in and reversed Trump's decision. What does that tell us about how power actually flows in this White House?
It suggests that Wiles has become the real arbiter of internal disputes—at least on health policy. Kennedy and Makary went through her, not directly to Trump. That's significant. It means if you want to survive in this administration, you need to know who controls access to the president.
But why did Loomer have that access in the first place? She's an influencer, not a government official.
That's the question everyone should be asking. She had Trump's ear on this one because she could frame it as a loyalty test. Old social media posts from a pandemic—that's the kind of thing that resonates with Trump's base and with Trump himself. But the real leverage was the pharmaceutical angle. She wasn't just enforcing ideology; she was protecting a company.
So this is about money, not principle?
It's both. Loomer genuinely believes in loyalty enforcement. But she's also aligned with corporate interests. Kennedy's faction sees health reform as the actual goal. Those two things are in direct conflict when a drug company's interests are at stake.
Will Kennedy win this?
He won this round. But Loomer is already moving on to his deputies. The real question is whether Trump will keep siding with Wiles and Kennedy, or whether Loomer's framing—that these people aren't loyal enough—will eventually stick. That's the battle being fought now.
And the American public just watches this play out?
For now, yes. But it matters because it determines who shapes FDA policy, who gets approved for drugs, what health reforms actually happen. The infighting is the policy.